Remove 2004 Remove 2020 Remove Cost Remove Metrics
article thumbnail

7 Strategies To Solve Your Business Problems Faster

Startup Professionals Musings

A broken process or a subtle quality issue can generate a flood of customer satisfaction problems, cost overruns, and loss of market share. Way back in 2004, he cared enough about an associate's injury to spend time investigating, and used the exercise to isolate a root cause without blaming anyone. Don’t waste time fixing symptoms.

Dividend 382
article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. Q: What is going to happen to the cost of capital? Q: What is the opportunity cost of not being in tech? One thing that jumps out quickly is that TVPI between 2004-2010 (avg 2.6x) has underperformed 2011-2017 (avg 3.0x). Ok, let’s jump in.

Valuation 319
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. Q: What is going to happen to the cost of capital? Q: What is the opportunity cost of not being in tech? One thing that jumps out quickly is that TVPI between 2004-2010 (avg 2.6x) has underperformed 2011-2017 (avg 3.0x). Ok, let’s jump in.

Valuation 295
article thumbnail

State of VC 2.0

View from Seed

Warning – this assumes some basic knowledge of VC performance metrics. Q: What is going to happen to the cost of capital? Q: What is the opportunity cost of not being in tech? One thing that jumps out quickly is that TVPI between 2004-2010 (avg 2.6x) has underperformed 2011-2017 (avg 3.0x). Ok, let’s jump in.

Valuation 156
article thumbnail

Top 15 ESG Startups to Watch in 2024

The Startup Magazine

The UN’s 2004 “Who Cares Wins” report was a major milestone, but it wasn’t until The Paris Agreement in 2015 that ESG took center stage, pushing companies to focus on environmental impact. trillion problem, and also a cost on the environment. A business that still holds fundamental value today.

article thumbnail

Out of the Crisis #5, ANA Therapeutics: a possible COVID-19 treatment and prophylactic

Startup Lessons Learned

And so, when we said that jokingly, Nadja diligently started going through the literature research, and in five minutes pulled up a paper saying, "Well, here's a paper that shows that during the SARS outbreak in 2004, niclosamide was actually a very potent inhibitor of viral replication." But I think that, again, this is hindsight being 2020.